TY - JOUR
T1 - The gut microbiome and cardiovascular disease
T2 - current knowledge and clinical potential
AU - Ahmad, Adilah F.
AU - Dwivedi, Girish
AU - O'Gara, Fergal
AU - Caparros-Martin, Jose
AU - Ward, Natalie C.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Cardiovascular disease (CVD) is the leading cause of death worldwide. The human body is populated by a diverse community of microbes, dominated by bacteria, but also including viruses and fungi. The largest and most complex of these communities is located in the gastrointestinal system and, with its associated genome, is known as the gut microbiome. Gut microbiome perturbations and related dysbiosis have been implicated in the progression and pathogenesis of CVD, including atherosclerosis, hypertension, and heart failure. Although there have been advances in the characterization and analysis of the gut microbiota and associated bacterial metabolites, the exact mechanisms through which they exert their action are not well understood. This review will focus on the role of the gut microbiome and associated functional components in the development and progression of atherosclerosis. Potential treatments to alter the gut microbiome to prevent or treat atherosclerosis and CVD are also discussed.
AB - Cardiovascular disease (CVD) is the leading cause of death worldwide. The human body is populated by a diverse community of microbes, dominated by bacteria, but also including viruses and fungi. The largest and most complex of these communities is located in the gastrointestinal system and, with its associated genome, is known as the gut microbiome. Gut microbiome perturbations and related dysbiosis have been implicated in the progression and pathogenesis of CVD, including atherosclerosis, hypertension, and heart failure. Although there have been advances in the characterization and analysis of the gut microbiota and associated bacterial metabolites, the exact mechanisms through which they exert their action are not well understood. This review will focus on the role of the gut microbiome and associated functional components in the development and progression of atherosclerosis. Potential treatments to alter the gut microbiome to prevent or treat atherosclerosis and CVD are also discussed.
KW - atherosclerosis
KW - cardiovascular disease
KW - dysbiosis
KW - microbiome
KW - short-chain fatty acids
KW - trimethylamine-N-oxide
UR - http://www.scopus.com/inward/record.url?scp=85073763691&partnerID=8YFLogxK
U2 - 10.1152/ajpheart.00376.2019
DO - 10.1152/ajpheart.00376.2019
M3 - Article
C2 - 31469291
SN - 0363-6135
VL - 317
SP - H923-H938
JO - American journal of physiology. Heart and circulatory physiology
JF - American journal of physiology. Heart and circulatory physiology
IS - 5
ER -